Use of growth factors with antiviral therapy for chronic hepatitis C

Clinics in Liver Disease

Volumn 9, Issue 3, 2005, Pages 439-451

  Curry, Michael P ^a,b   Afdhal, Nezam H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DARBOPOIETIN ALPHA; ERYTHROPOIETIN; GROWTH FACTOR; INTERFERON; NEORECORMAN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANEMIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CAPILLARY LEAK SYNDROME; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DYSERYTHROPOIESIS; DYSPNEA; EDEMA; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL DISEASE; HEART FAILURE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEUKOPENIA; LUNG EDEMA; MENTAL DISEASE; NAUSEA; NEUTROPENIA; PLEURA EFFUSION; PURE RED CELL ANEMIA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; NEUTROPENIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RIBAVIRIN; THROMBOCYTOPENIA;

EID: 22044451336     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.05.012     Document Type: Review

References (38)

1. M.J. Alter, D. Kruszon-Moran, and O.V. Nainan The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
2. N.H. Afdhal The natural history of hepatitis C Semin Liver Dis 24 Suppl 2 2004 3 8
3. S.H. Belle, K.C. Beringer, and K.M. Detre Recent findings concerning liver transplantation in the United States Clin Transpl 1996 15 29
4. S. Vong, and B.P. Bell Chronic liver disease mortality in the United States, 1990-1998 Hepatology 39 2004 476 483
5. J.B. Wong, G.M. McQuillan, and J.G. McHutchison Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 2000 1562 1569
6. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
7. T. Poynard, J. McHutchison, and M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
8. D. Bernstein, L. Kleinman, and C.M. Barker Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients Hepatology 35 2002 704 708
9. N.H. Afdhal, D.T. Dieterich, and P.J. Pockros Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
10. J.G. McHutchison, S.C. Gordon, and E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492
11. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
12. PEG-Intron. (peginterferon alfa-2b) powder for injection: prescribing information. Kenilworth (NJ): Schering Corportation
13. Pegasys. (peginterferon alfa-2a) prescribing information. Nutley (NJ): Hoffman-LaRoche Inc
14. J.G. McHutchison, M. Manns, and K. Patel Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
15. P. Ferenci, M. Shiffman, and M.W. Fried Early prediction of response to 40kDa peginterferon alfa-2a (Pegasys) plus ribavirin (RBV) in patients with chronic heaptitis C (CHC) Hepatology 34 2001 351A
16. S.J. Hadziyannis, H. Sette Jr, and T.R. Morgan Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
17. P.G. Canonico, M.D. Kastello, and C.T. Spears Effects of ribavirin on red blood cells Toxicol Appl Pharmacol 74 1984 155 162
18. C.M. Bruno, S. Neri, and C. Sciacca Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases World J Gastroenterol 10 2004 1353 1356
19. M. Peck-Radosavljevic, M. Wichlas, and M. Homoncik-Kraml Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha Gastroenterology 123 2002 141 151
20. M.S. Sulkowski, R. Wasserman, and L. Brooks Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection J Viral Hepat 11 2004 243 250
21. F.J. Torriani, M. Rodriguez-Torres, and J.K. Rockstroh Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
22. F. Carrat, F. Bani-Sadr, and S. Pol Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2004 2839 2848
23. A.K. Shergill, M. Khalili, and S. Straley Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation Am J Transplant 5 2005 118 124
24. J. Dumortier, J.Y. Scoazec, and P. Chevallier Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination J Hepatol 40 2004 669 674
25. A.H. Talal, K. Weisz, and T. Hau A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha Am J Gastroenterol 96 2001 2802 2804
26. A.E. Gergely, P. Lafarge, and I. Fouchard-Hubert Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C Hepatology 35 2002 1281 1282
27. D.T. Dieterich, R. Wasserman, and N. Brau Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
28. P.J. Pockros, M.L. Shiffman, and E.R. Schiff Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
29. N. Casadevall, J. Nataf, and B. Viron Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N Engl J Med 346 2002 469 475
30. C.L. Bennett, S. Luminari, and A.R. Nissenson Pure red-cell aplasia and epoetin therapy N Engl J Med 351 2004 1403 1408
31. M.L. Shiffman, T.R. Morgan, and M.G. Ghany The impact of PegInterferon (PEGIFN) and Ribavirin (RBV) dosing on sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) undergoing treatment Hepatology 40 2004 314A
32. S. Wong, K. Kaita, and T. Gauthier A comparative trial of recombinant interferon alpha 2A versus alpha 2 beta on myelosuppression in healthy adult volunteers Hepatogastroenterology 43 1996 301 305
33. G.L. Davis, R. Esteban-Mur, and V. Rustgi Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1493 1499
34. A. Soza, J.E. Everhart, and M.G. Ghany Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C Hepatology 36 2002 1273 1279
35. P.J. Pockros, A. Duchini, and R. McMillan Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection Am J Gastroenterol 97 2002 2040 2045
36. B.C. Medeiros, P.A. Seligman, and G.T. Everson Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavirin treatment for hepatitis C J Clin Gastroenterol 38 2004 84 86
37. M. Peck-Radosavljevic, M. Wichlas, and J. Pidlich Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C Hepatology 28 1998 1424 1429
38. V. Rustgi, P. Lee, and S. Finnegan Safety and efficacy of recombinant human IL-11 (Oprelvekin) in combination with interferon/ribavirin therapy in hepatitis c patients with thrombocytopenia Hepatology 36 2002 361A